Tilt Biotherapeutics Ltd.

This early-stage study tests a new approach for people with advanced melanoma that has not responded to standard treatments. Nine participants will receive a special virus (TILT-123) designed to boost the immune system, along with chemotherapy and their own lab-grown immune cells…

This early-stage trial tests a specially designed virus (TILT-123) that targets and kills cancer cells while also boosting the immune system. It is given together with the immunotherapy drug pembrolizumab (Keytruda) and sometimes chemotherapy, to women with ovarian cancer that no…

This early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that targets cancer cells with pembrolizumab, an immunotherapy drug. Th…